Pharmacotherapy of insomnia

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 3, 2008, Pages 351-362

  Bhat, Abid ^a   Shafi, Fariha ^a   El Solh, Ali A ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Benzodiazepine; Benzodiazepine receptor agonist; Insomnia; Melatonin; Total sleep time

Indexed keywords

AMIODARONE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CALCIUM; CENTRAL DEPRESSANT AGENT; CIPROFLOXACIN; DIPHENHYDRAMINE; ESZOPICLONE; FLUCONAZOLE; FLUVOXAMINE; GABOXADOL; HYPERICUM PERFORATUM EXTRACT; HYPNOTIC AGENT; INDIPLON; KETOCONAZOLE; MELATONIN; MUSCLE RELAXANT AGENT; PLACEBO; RAMELTEON; RETINOL; TIAGABINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; 4 AMINOBUTYRIC ACID A RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYPNOTIC SEDATIVE AGENT; MELATONIN RECEPTOR; NEUROLEPTIC AGENT;

ATAXIA; BEDTIME DOSAGE; BINDING AFFINITY; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONTROLLED RELEASE FORMULATION; COORDINATION DISORDER; DAILY LIFE ACTIVITY; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; HALLUCINATION; HANGOVER; HIGH RISK PATIENT; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; INCIDENCE; INSOMNIA; MEMORY DISORDER; MENTAL DISEASE; NAUSEA; NONHUMAN; PARESTHESIA; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRAFFIC ACCIDENT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA; ALTERNATIVE MEDICINE; BEHAVIOR THERAPY;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; BENZODIAZEPINES; CENTRAL NERVOUS SYSTEM DEPRESSANTS; COGNITIVE THERAPY; COMPLEMENTARY THERAPIES; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; RECEPTORS, GABA-A; RECEPTORS, MELATONIN; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 39049124764     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.3.351     Document Type: Review

References (103)

1. Ohayon M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6(2):97-111
2. Roth T. Insomnia definition, prevalence, etiology and consequences. JCSM 2007;3:S7-10
3. Hohagen F, Kappler C, Schramm E, et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551-4
4. Ohayon M, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep 1997;20:715-23
5. Ohayon M, Caulet M, Priest RG, et al. DSM-IV and ICSD-90 insomnia symptoms and sleep dissatisfaction. Br J Psychiatry 1997;171:382-8
6. Li RH, Wing YK, Ho SC, et al. Gender differences in insomnia: a study in the Hong Kong Chinese population. J Psychosom Res 2002;53:601-9
7. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 1991;52(Suppl):16-23
8. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey II. Sleep 1999;22(Suppl):S354-8
9. Kuppermann M, Lubeck DP, Mazonson PD, et al. Sleep problem and their correlates in a working population. J Gen Int Med 1995;10:25-32
10. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22:S386-93
11. Ozminkowski RJ, Wang S, Walsh J. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007;30:263-73
12. Katz DA, McHorney CA. The relationship between insomnia and health related quality of life in patients with chronic illness. J Fam Pract 2002;51:229-35
13. Espie CA. Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorders in adults. Ann Rev Psychol 2002;53:215-43
14. Montgomery P, Dennis J. A systematic review of nonpharmacological therapies for sleep problems later in life. Sleep Med Rev 2004;8:47-62
15. Smith MT, Perlis ML, Park A. et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia, Am J Psychiatry 2002;159:5-11
16. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991-9
17. Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003;7:215-25
18. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22:371-5
19. Asnis GM, Chakraburtty A, Duboff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999;60:668-76
20. Fava M, McCall WV, Krystal A, et al. Eszopiclone coadministered with Fluoxetine in patients with insomnia coexisting with major depressive disorder. Bio Psychiatry 2006,59:1052-60
21. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp ther 2002;300:2-8
22. Burt DR. Reducing GABA receptors. Life Sci 2003;73:1742-58
23. Smith AJ, Alder L, Silk J, et al. Effect of α-subunit on allosteric modulation of ion channel function in stably expressed human recombinant γ-aminobutyric add receptors determined using 36 Cl ion flux. Mol Pharmacol 2001;59:1108-18
24. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid (A) receptor subtypes. Nature 1999;401:796-800
25. Bowery NG. GABAB receptor pharmacology. Ann Rev Pharmacol Toxicol 1993;33:109-47
26. Couve A, Moss SJ, Pangalos MN. GABAB receptors: a new paradigm in G protein signaling. Mol Cell Neurosci 2000;16:296-312
27. Ng GY, Clark J, Coulombe N, et al. Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J Biol Chem 1999;274:7607-10
28. Shimada S, Cutting G, Uhl GR. Gamma-aminobutyric acid A or C receptor? Gamma-aminobutyric acid rho 1 receptor RNA induces bicuculline-, barbiturate-, and benzodiazepine- insensitive gamma-aminobutyric acid responses in Xenopus oocytes. Mol Pharmacol 1992,41:683-7
29. Woodward M. Hypnosedatives in the elderly. CNS Drugs 1999;11:263-79
30. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-7
31. Holbrook AM, Crowther R, Lotter A. et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-33
32. Allen RP, Mendells J, Nevins D, et al. Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months. J Clin Pharmacol 1987;27:768-75
33. Roth T, Roehrs TA. A review of safety profiles on benzodiazepine hypnotics. J Clin Psychiatry 1992;52(Suppl):3841
34. Meddelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992;53(Suppl):8-9
35. Holbrook A, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-33
36. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly. who is at greatest risk? Arch Int Med 2004;164:1567-72
37. Scharf M, Roth T, Vogel G. Walsh J. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 2004;55:192-9
38. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-89
39. Ambien [package insert]. New York, NY: Sanofi-Synthelabo, Inc.; March 2004
40. Elie R, Ruther F. Farr I, et al.; for the Zaleplon Clinical Study Group. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 1999;60:536-44.
41. Damgen K, Luddens H. Zaleplon displays selectivity to recombinant GABAA receptors diffierent from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999;25(3):139-48
42. Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA (A) receptor subtypes. Eur J Pharmacol 2002,451:103-10
43. Walsh JY, Pollak CP, Scharf MB, et al. Lack of residual sedation f6llowing middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000;23:17-21
44. Zammit GK, Corser B, Doghramji K, et al. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med 2006;2(4):417-23
45. Ancoli-Israel S, Walsh JK, Mangano RM, et al. Zaleplon, a novel nonbenzodiazepine hypnoti, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1:114-20
46. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9
47. Roth T, Walsh JK, Krystal AD, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia, Sleep Med 2005;6:487-95
48. Walsh JK, Krystal AD, Amato AD, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effects on sleep, quality of life, and work limitations. Sleep 2007;30(8):959-68
49. McCall WV, Erman M, Krystal AD, et al. A polysomnographic study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22(9):1633-42
50. Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005;20:27-37
51. Miyamoto M, Nishikawa H, Doken Y, et al. The slecp-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004;27:1319-25
52. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian Phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998;21:52-68
53. Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs Sleep 1995;18:598-603
54. Macfarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 1991;30(4):371-6
55. Almeida Moores LG, Ontiveros Uribe MP, Cortes Sotres J, et al. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci 2003;28(3):191-6
56. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41-50
57. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004;116:91-5
58. Haimov I, Laudon, Zisapel L, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:167
59. Sack RL, Brandes RW, Kendall AR, et al. Entrainment of free-running circadian rhydims by melatonin in blind people. N Engl J Med 2000;343:1070-7
60. Ekmekcioglu C. Melatonin receptors in humans; biologic role and clinical relevance. Biomed Pharmacother 2006;60(3):97-108
61. Stevenson S, Cornelissen K, Clarke E, et al. Study of the absorption, metabolism, and excretion of ramelteon (TAK-375) [abstract]. Clin Pharmacol Ther 2004;75:P22 [Abstract PI-74]
62. Tolbert D, Karim A. Zhao Z. Evaluation of the single and multiple dose pharmacokinetics of ramelteon (TAK-375) in subjects with and without renal impairment. J Clin Pharmacol 2004;44:1210 [Abstract]
63. Sainati SM, Karim A. Tolbert D. Effects of multiple doses of fluoxetine on the systemic exposure of a single dose of ramelteon (TAK-375) in healthy adults. Sleep 2004;27-A48 [Abstract]
64. Karim A. Tolbert D, Cao C, et al. Effects of fluconazole and ketoconazole on the pharmacokinetics of ramelteon (TAK-375) in normal healthy male and female subjects. Sleep 2004;27:A53-4 [Abstract]
65. Rozerem (ramelteon) [package insert]. Available at http://www.rozerem.com/images/PI.pdf [Accessed 16 December 2006]
66. Miyamoto M, Nishikawa H, Doken Y, et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004;27:1319-25
67. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28:303-7
68. Erman M, Seiden D, Zammit G, et al. An efficacy, safety and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24
69. Zammit G, Roth T, Erman M, et al. Double-blind placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia, Sleep 2005;28A-228 [Abstract]
70. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7(4):312-8
71. Stubbs C, Karim A. A safety, tolerance, and pharmacokinetic study of five single doses of TAK-375 in healthy adults. Sleep 2003;26:A76
72. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/ MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28:303-7
73. McGechan A. Wellington K. Ramelteon. CNS Drugs 2005;19:1057-67
74. Erman M, Selden D, Zammit G, et al. An efficacy, safety, and dose response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24
75. Kato K, Hirai K, Nishiyama J, et al. Neurochemical properties of ramelteon (TAK-375), as selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301-10
76. Griffiths RR, Johnson MW, Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005;66(Suppl 9):31-41
77. Walsh JK. Drugs used to treat insomnia in 2002: regulatory based rather than evidence based medicine. Sleep 2004;27:1441-2
78. Mendelson WB. A review of the evidence for efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005;66(4):469-76
79. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998;13:191-8
80. Yamadera. H, Nakumar S, Suzuki H, et al. Effects of trazodone hypochloride and imipramine on polysomnography in healthy subjects. Pysch Clin Neurosci 1998;52:439-43
81. Montgomery I, Oswald I, Morgan K, et al. Thazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol. 1983;16:139-44
82. Carson CC III, Mino RD. Priapism associated with trazodone therapy. J Urol 1988;139:369-70
83. Compton-McBride S, Schweitzer PK, Walsh JK. Most commonly used drugs to treat insomnia in 2002. Sleep 2004;27(Suppl):A255
84. Winokur A, Demartinis NA, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Crin Psychiatry 2003;64:1224-9
85. Schirrecatte M, Dumont F, Machowski R, et al. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002;46:197-201
86. Winokur A. Sateia MJ, Hayes JB, et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients; a pilot study. Biol Psychiatry 2000;48(1):75-8
87. Winokur A, Demartinis NA, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003;64:1224-9
88. Sorensen M, Jorgensen J, Viby-Mogensen J, et al. Double blind group comparative study using the new antidepressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynecological surgery. Acta Psychiatr Scand 1987;71(4):339-46
89. Rodenbeck A, Cohrs S, Jordan W, et al. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology 2003;170:423-8
90. Hajak G, Rodenbeck A, Adler L, et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmapsychiatry 1996;29:187-92
91. Hsu T, Rogowski R, Roth T. Low-dose doxepin in the treatment of primary Insomnia. Program and Abstracts of the Associated Professional Sleep Societies 19th Annual Meeting; 2005, June 18 - 23, Denver, Colorado [Abstract 0150]
92. Salin-Pascual RJ, Herrera-Estrella M, Galicia Polo L, et al. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999;46(1):141-3
93. Sullivan SK, Petroski RE, Verge G, et al. Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative/hypnotic with the GABA A receptor. J Pharmacol Exp Ther 2004;311:537-46
94. Foster AC, Pellymounter MA, Cullen JM, et al. In vivo pharmacologic characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J Pharmacol ExpTher 2004;311:547-59
95. Lankford J, Lydiard R, Walsh JK, et al. Efficacy and tolerability of Indiplon-MR in elderly patients with chronic insomnia: results of a double-blind, placebo-controlled 2-week trial. J Clin Sleep Med 2006;2:309-15
96. Scharf MB, Black J, Hull S, et al. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controtled, 3-month study. Sleep 2007;30(6):743-52
97. Walsh JK, Perlis M, Rosenthal M, et al. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med 2006;2(1):35-41
98. Roth T, Wright K Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006;29:335-41
99. Deacon S, Staner L, Staner C, et al. Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia. Sleep 2007;30(3):281-7
100. Lundahl J, Staner L, Staner C. et al. Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia. Psychopharmacology 2007;195(1):139-46
101. Kupfer D. Depression and associated sleep disturbances: patient benefits with agomelatin. Eur Neuropsychopharmacol 2006;16(5):S639-43
102. Rchardson GS, Roehrs TA. Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:511-15
103. Vgontzas AN, Zoumakis E, Papanicolaou DA, et al. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism 2002;51:887-92